Reinventing Arena to focus on Phase II clinical candidates

In the six months after joining Arena Pharmaceuticals as CEO, Dr. Amit Munshi has been busy: reducing the company’s commitment to obesity drug Belviq, which it has partnered with Eisai; spinning out the discovery research activities into a new company, Beacon Discovery; and prioritizing three Phase II programs with readouts in 2017. Munshi updates Mike Ward, global director of content at Informa Pharma Intelligence’s insights portfolio, on the company’s progress to date.